ERBB2 and ovarian neoplasm: Simply mixing mPEG × HER2 with PLD can easily provide tumor specificity and lead PLD to actively target HER2-overexpressed ovarian tumors and further trigger receptor-mediated endocytosis, thereby enhancing cytotoxicity and therapeutic efficacy in ovarian cancer (Supplementary Figure S1).